CEO Highlights How Chronix Biomedical's Unique Blood Tests Can Enable Early Cancer Diagnosis and Personalized Treatment at Payor Oncology Conference  
11/16/2010 10:24:40 AM

BALTIMORE & SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced that its Chief Executive Officer, Dr. Howard Urnovitz, is presenting a session on “Improving Technology for Cancer Detection and Screening” at the Payor Oncology Management Summit, a conference for healthcare insurers and providers focusing on new developments in cancer diagnosis, treatment and prevention. Chronix is developing disease-specific epigenomic biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum tests are applicable to a wide range of cancers and other chronic diseases.